Hematopoietic Recovery and Safety Following Early Romiplostim Administration After Pediatric HSCT: A Prospective Randomized Pilot Study.
Sanjana Sarangarajan, Aditya Kumar Gupta, Jagdish Prasad Meena et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the safety and effects of early romiplostim administration in 32 children undergoing hematopoietic stem cell transplantation (HSCT). The study found that while romiplostim did not significantly reduce the time to platelet engraftment (12 vs. 12.5 days; p = 0.88), it was safe and associated with higher platelet and neutrophil counts by Day +28, particularly in those receiving allogeneic HSCT.
Key findings
- Median time to platelet engraftment was 12 days for romiplostim and 12.5 days for control (p = 0.88).
- By Day +28, higher platelet counts were observed in the romiplostim group.
- Romiplostim recipients had higher absolute neutrophil counts on Day +28.
- No thrombotic events or severe bleeding episodes were reported.
Why it matters
Delayed platelet recovery after HSCT can lead to significant complications, including increased transfusion needs and prolonged hospitalization. Understanding the role of romiplostim in this context may inform future treatment strategies to enhance recovery.